A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Phase 2 Recruiting
49 enrolled
KEYVIBE-005
Phase 2 Completed
613 enrolled
Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
Phase 2 Terminated
22 enrolled 5 charts
Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer
Phase 2 Completed
25 enrolled
MATEO
Phase 2 Completed
242 enrolled
Induction Chemotherapy Followed by Chemoradiotherapy in Esophageal Cancer
Phase 2 Completed
110 enrolled
T+TP
Phase 2 Unknown
44 enrolled
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
Phase 2 Completed
213 enrolled 17 charts
Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer
Phase 2 Completed
39 enrolled 10 charts
Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.
Phase 2 Completed
27 enrolled 10 charts
SEED
Phase 2 Unknown
98 enrolled
Avastin and Taxotere for Esophagogastric Cancer
Phase 2 Completed
42 enrolled
Endostatin Combined With Chemotherapy for Adjuvant Treatment of Esophageal Cancer
Phase 2 Unknown
186 enrolled
Pre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder Resectable Esophagus Cancer
Phase 2 Terminated
170 enrolled
Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2 Completed
40 enrolled 10 charts
Docetaxel and S-1 for Advanced Esophageal Cancer
Phase 2 Unknown
37 enrolled
Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
Phase 2 Completed
38 enrolled 10 charts
Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery
Phase 2 Completed
29 enrolled 12 charts
Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction
Phase 2 Completed
46 enrolled
Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma
Phase 2 Unknown
120 enrolled
Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach
Phase 2 Completed
47 enrolled
Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy
Phase 2 Completed
6 enrolled 6 charts
Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
Phase 2 Completed
48 enrolled 8 charts
Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction
Phase 2 Completed
70 enrolled 15 charts
Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma
Phase 2 Completed
22 enrolled 6 charts
Chemotherapy Induction and Chemoradiotherapy in Patients With Esophageal Carcinoma
Phase 2 Terminated
50 enrolled
Combination Chemotherapy Followed by Surgery and Intraperitoneal Chemotherapy in Treating Patients With Locally Advanced Stomach Cancer
Phase 2 Completed
A Study to Evaluate the Combination of Cetuximab and Chemotherapy as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab in Locoregional Esophageal Carcinoma
Phase 2 Completed
50 enrolled
Neoadjuvant Docetaxel and Cisplatin Plus Chemoradiotherapy Followed By Surgery in Treating Patients With Locally Advanced, Resectable Esophageal Cancer
Phase 2 Completed
66 enrolled
DCXAIOCHARITE
Phase 2 Unknown
50 enrolled
Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer
Phase 2 Completed
54 enrolled